Cancer Res Treat.  2003 Feb;35(1):30-34.

A Multi-Center, Phase II Clinical Trial of Genexol(R) (Paclitaxel) and Cisplatin for Patients with Non-Small Cell Lung Cancer

Affiliations
  • 1Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. bangyj@plaza.snu.ac.kr
  • 2Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • 3Department of Internal Medicine, Asan Medical Center, Ulsan University College of Medicine, Seoul, Korea.
  • 4Department of Internal Medicine, St. Vincent's Hospital, Catholic University College of Medicine, Suwon, Korea.
  • 5Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.

Abstract

PURPOSE
A combination of paclitaxel and cisplatin is an effective and safe regimen for advanced non-small cell lung cancer (NSCLC). We conducted a multi-center, phase II trial to evaluate the efficacy and safety of Genexol(R) (paclitaxel) and cisplatin in patients with NSCLC. MATERIALS AND METHODS: Chemotherapy-na ve patients having histologically confirmed NSCLC were enrolled. Genexol(R) was administered at 175 mg/m2 as a 3-hour intravenous infusion and cisplatin at 75 mg/m2 as an intravenous infusion on day 1 every 3 weeks. RESULTS: Twenty-five of 27 patients that were entered from 5 hospitals between Jan 2001 and Aug 2001 received chemotherapy. On an intent-to-treat basis, 9 patients (36%) achieved a partial response, 7 patients (28%) a stable disease, and 5 patients (20%) The overall response rate was 36% (95% CI, 17 to 55%). progressed. The median duration of the response was 7.8 months (95% CI, 6.6 to 9.0 months). The median time to progression was 7.4 months (95% CI, 5.3 to 9.5 months), and median overall survival was 13.3 months (95% CI, 10.8 to 15.9 months) for the intent-to-treat population. The major oxicity was hematological, with grade 3 and 4 neutropenia in 10% (10/106) of the total cycles. The non-hematologic oxicity was mild, and grade 3 emesis was observed in 2 patients (8%). One patient experienced a moderate degree hypersensitivity reaction. CONCLUSION: The results suggest that a combination of Genexol(R) and cisplatin is an effective and well-tolerated regimen for patients with NSCLC.

Keyword

Non-small cell lung neoplasm; Chemotherapy; Genexol; Paclitaxel; Cisplatin

MeSH Terms

Carcinoma, Non-Small-Cell Lung*
Cisplatin*
Drug Therapy
Humans
Hypersensitivity
Infusions, Intravenous
Neutropenia
Paclitaxel
Vomiting
Cisplatin
Paclitaxel
Full Text Links
  • CRT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr